Clinical Trials Logo

EBV-Positive DLBCL, Nos clinical trials

View clinical trials related to EBV-Positive DLBCL, Nos.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05583149 Recruiting - Clinical trials for Refractory B-Cell Non-Hodgkin Lymphoma

Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas

Start date: March 1, 2023
Phase: Phase 2
Study type: Interventional

This research is being done to assess the effectiveness and safety of acalabrutinib combined with lisocabtagene maraleucel (liso-cel) for people with relapsed/refractory aggressive B-cell lymphoma. This research study involves the study drug acalabrutinib in combination with lisocabtagene maraleuce

NCT ID: NCT05544019 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Study of SGR-1505 in Mature B-Cell Neoplasms

Start date: April 10, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.

NCT ID: NCT05011058 Recruiting - Clinical trials for EBV-Positive DLBCL, NOS

An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas

NAVAL-1
Start date: May 28, 2021
Phase: Phase 2
Study type: Interventional

A Phase 2 study to evaluate the efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive lymphomas

NCT ID: NCT04796857 Recruiting - Clinical trials for High-grade B-cell Lymphoma

Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL

Start date: March 31, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

Aim of this study will evaluate the efficacy and safety of tislelizumab in combination with lenalidomide in in patients with relapsed or refractory Elderly Patients with non-GCB Diffuse Large B Cell Lymphoma

NCT ID: NCT04705129 Recruiting - Clinical trials for Primary Mediastinal Large B Cell Lymphoma

Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCL

Start date: January 1, 2021
Phase: Phase 2
Study type: Interventional

The study is to investigate the safety and efficacy of Zanubrutinib combined with Tislelizumab in the treatment of relapsed/refractory primary mediastinal large B-cell lymphoma and Epstein-Barr Virus-positive diffuse large B-cell lymphoma.

NCT ID: NCT04476459 Recruiting - Clinical trials for Diffuse Large B Cell Lymphoma

Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL

Start date: July 23, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This study will evaluate the efficacy and safety of camrelizumab in combination with apatinib in in patients with relapsed or refractory diffuse large B cell lymphoma failed from second line chemotherapy.

NCT ID: NCT04181489 Recruiting - Clinical trials for EBV-Positive DLBCL, Nos

Sintilimab in Combination With R-CHOP in Patients With Treatment-naive EBV-positive DLBCL, NOS

Start date: January 1, 2019
Phase: Phase 2
Study type: Interventional

The prognosis of EBV+ DLBCL is dismal. Previous study showed that high level of PD-L1 expression in EBV+ DLBCL. The investigators therefore design this phase II study to investigate the safety and efficacy of sintilimab (an anti-PD-1 antibody) in combination with R-CHOP in patients with treatment-naive EBV+ DLBCL.

NCT ID: NCT04058470 Recruiting - Clinical trials for Diffuse Large B Cell Lymphoma

Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma

Start date: April 24, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

1. Phase I portion of this study will evaluate the efficacy and saftey of toripalimab plus rituximab in treating untreated elderly diffuse large B cell lymphoma patients. 2. The aim of phase II portion of this study will evaluate the efficacy and saftey of toripalimab plus rituximab followed by R-CHOP(rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) regimen in treating untreated elderly diffuse large B cell lymphoma patients.